<div id="readability-page-1"><p>In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Beam Therapeutics, with a price target of <span id="expert-recommendation-target">$43.00</span>.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Revolution Medicines, and Crispr Therapeutics AG. According to TipRanks, Stranahan has an average return of <span>5.4%</span> and a 55.04% success rate on recommended stocks. </p> <p>In addition to Bank of America Securities, Beam Therapeutics also received a Buy from Bernstein’s William Pickering in a report issued on December 1. However, on November 26, TR | OpenAI – 4o reiterated a Hold rating on Beam Therapeutics (NASDAQ: BEAM).</p></div>

BEAM

<p>Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Beam Therapeutics with a $43 price target. Stranahan, who covers the Healthcare sector, has a 5.4% average return and a 55.04% success rate. Beam Therapeutics also received a Buy rating from Bernstein's William Pickering, while TR | OpenAI reiterated a Hold rating on November 26.</p>

Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities